March 6, 2024
An Introduction to Treating Patients with Buprenorphine
8:00 a.m. – 12:00 p.m.
(Meets SUD training requirements for prescribers)

During May 2020–April 2021, the estimated number of drug overdose deaths in the United States exceeded 100,000 over a 12-month period for the first time. Medications for Opioid Use Disorder (MOUD), like Buprenorphine, methadone, and naltrexone have been proven to reduce overdose and death and providers that hold a DEA license with Schedule III Authority can prescribe Buprenorphine. Ensuring prescribers have the knowledge to initiate MOUD is imperative to helping patients with opioid use disorder. Q&A and discussion to follow.

Financial Incentive:

BCBSM will provide a $250 incentive to Primary Care Physicians who attend this MOUD training. The incentive will be limited to the first 250 registered primary care physicians, so please register early to ensure a spot.

4 CME Credits PENDING – Meets DEA SUD Training Requirements

Learning Objectives:

  • Understand the basics of the neurobiology of addiction
  • Understand the basic pharmacodynamics of buprenorphine
  • Describe the diagnosis, intake, buprenorphine induction of a patient with OUD.
  • Understand how to manage acute and chronic pain for patients with opioid use disorder with a specific emphasis on using buprenorphine for pain management
  • Describe key principles in outpatient management of patients with OUD


  • Sheba Sethi, MD
  • Chris Frank, MD, PhD